Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
AZASITE vs ERYTHROMYCIN AND BENZOYL PEROXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Erythromycin is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Benzoyl peroxide has bactericidal effects against Propionibacterium acnes, likely through the release of free radical oxygen that oxidizes bacterial proteins. It also has keratolytic and comedolytic properties.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
Topical: Apply a thin layer to affected areas once daily in the evening.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Erythromycin: 1.4–2.0 hours (terminal half-life in adults). Benzoyl peroxide: Not applicable; it is a topical agent with negligible systemic absorption.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Erythromycin is primarily excreted via bile (fecal elimination) with approximately 15% excreted unchanged in urine. Benzoyl peroxide is degraded to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted renally; less than 5% is excreted unchanged in urine.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic